(FIGS) Figs - Ratings and Ratios
Scrubs, Apparel, Footwear, Accessories, Loungewear
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 66.5% |
| Value at Risk 5%th | 90.5% |
| Relative Tail Risk | -17.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 101.21 |
| CAGR/Max DD | 0.15 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.314 |
| Beta | 1.059 |
| Beta Downside | 0.996 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.02% |
| Mean DD | 34.99% |
| Median DD | 37.33% |
Description: FIGS Figs November 18, 2025
FIGS, Inc. (NYSE: FIGS) is a Santa Monica-based direct-to-consumer (DTC) apparel company that designs, manufactures, and sells medical-scrub and lifestyle clothing to healthcare professionals in the U.S. and Canada through its website, mobile app, B2B channel, and a limited brick-and-mortar footprint.
Beyond core scrubs, the product portfolio now includes outerwear, compression socks, lab coats, loungewear, performance leggings, and accessories such as badge reels and tote bags. In FY 2023 the company reported roughly $1.2 billion in revenue, a 30% year-over-year increase, and a gross margin of about 55%, with DTC sales accounting for roughly 70% of total revenue-a metric that underpins its pricing power and customer-data advantage.
Key growth drivers include the ongoing shortage of healthcare staff, which fuels demand for comfortable, durable workwear, and inflation-adjusted pricing that has allowed FIGS to maintain margin expansion despite higher input costs. The health-care supplies sector’s base-rate growth of ~4% annually (per S&P Health Care Supplies index) provides a tailwind, while competition from legacy uniform brands and emerging DTC entrants remains a risk.
For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for drilling into FIGS’s valuation metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (17.6m TTM) > 0 and > 6% of Revenue (6% = 34.9m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -5.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 57.03% (prev 61.89%; Δ -4.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 30.7m > Net Income 17.6m (YES >=105%, WARN >=100%) |
| Net Debt (7.66m) to EBITDA (41.0m) ratio: 0.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (180.9m) change vs 12m ago 6.29% (target <= -2.0% for YES) |
| Gross Margin 67.98% (prev 67.67%; Δ 0.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 106.9% (prev 101.1%; Δ 5.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.88 (EBITDA TTM 41.0m / Interest Expense TTM -5.55m) >= 6 (WARN >= 3) |
Altman Z'' 5.52
| (A) 0.61 = (Total Current Assets 418.0m - Total Current Liabilities 86.7m) / Total Assets 544.7m |
| (B) 0.15 = Retained Earnings (Balance) 80.2m / Total Assets 544.7m |
| (C) 0.06 = EBIT TTM 32.7m / Avg Total Assets 543.6m |
| (D) 0.61 = Book Value of Equity 80.4m / Total Liabilities 131.4m |
| Total Rating: 5.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.59
| 1. Piotroski 4.0pt |
| 2. FCF Yield 1.56% |
| 3. FCF Margin 3.78% |
| 4. Debt/Equity 0.13 |
| 5. Debt/Ebitda 0.19 |
| 6. ROIC - WACC (= -3.85)% |
| 7. RoE 4.50% |
| 8. Rev. Trend 60.43% |
| 9. EPS Trend -43.88% |
What is the price of FIGS shares?
Over the past week, the price has changed by +12.29%, over one month by +40.92%, over three months by +60.66% and over the past year by +99.26%.
Is FIGS a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 7
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the FIGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.8 | -18.6% |
| Analysts Target Price | 8.8 | -18.6% |
| ValueRay Target Price | 12.9 | 19.8% |
FIGS Fundamental Data Overview November 29, 2025
P/E Trailing = 88.4545
P/E Forward = 108.6957
P/S = 2.7547
P/B = 3.8724
Beta = 1.342
Revenue TTM = 581.0m USD
EBIT TTM = 32.7m USD
EBITDA TTM = 41.0m USD
Long Term Debt = 54.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.45m USD (from shortTermDebt, last quarter)
Debt = 54.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.66m USD (from netDebt column, last quarter)
Enterprise Value = 1.41b USD (1.60b + Debt 54.1m - CCE 241.5m)
Interest Coverage Ratio = -5.88 (Ebit TTM 32.7m / Interest Expense TTM -5.55m)
FCF Yield = 1.56% (FCF TTM 22.0m / Enterprise Value 1.41b)
FCF Margin = 3.78% (FCF TTM 22.0m / Revenue TTM 581.0m)
Net Margin = 3.03% (Net Income TTM 17.6m / Revenue TTM 581.0m)
Gross Margin = 67.98% ((Revenue TTM 581.0m - Cost of Revenue TTM 186.1m) / Revenue TTM)
Gross Margin QoQ = 69.94% (prev 66.99%)
Tobins Q-Ratio = 2.59 (Enterprise Value 1.41b / Total Assets 544.7m)
Interest Expense / Debt = 14.50% (Interest Expense 7.85m / Debt 54.1m)
Taxrate = 26.87% (3.21m / 12.0m)
NOPAT = 23.9m (EBIT 32.7m * (1 - 26.87%))
Current Ratio = 4.82 (Total Current Assets 418.0m / Total Current Liabilities 86.7m)
Debt / Equity = 0.13 (Debt 54.1m / totalStockholderEquity, last quarter 413.3m)
Debt / EBITDA = 0.19 (Net Debt 7.66m / EBITDA 41.0m)
Debt / FCF = 0.35 (Net Debt 7.66m / FCF TTM 22.0m)
Total Stockholder Equity = 392.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.24% (Net Income 17.6m / Total Assets 544.7m)
RoE = 4.50% (Net Income TTM 17.6m / Total Stockholder Equity 392.1m)
RoCE = 7.32% (EBIT 32.7m / Capital Employed (Equity 392.1m + L.T.Debt 54.1m))
RoIC = 6.09% (NOPAT 23.9m / Invested Capital 392.1m)
WACC = 9.94% (E(1.60b)/V(1.65b) * Re(9.92%) + D(54.1m)/V(1.65b) * Rd(14.50%) * (1-Tc(0.27)))
Discount Rate = 9.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF Debug] Terminal Value 62.48% ; FCFE base≈33.5m ; Y1≈22.0m ; Y5≈10.1m
Fair Price DCF = 0.96 (DCF Value 149.3m / Shares Outstanding 156.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -43.88 | EPS CAGR: -14.51% | SUE: 2.09 | # QB: 2
Revenue Correlation: 60.43 | Revenue CAGR: 4.48% | SUE: 1.61 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.00 | Chg30d=+0.006 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=+0.030 | Revisions Net=+10 | Growth EPS=+1.4% | Growth Revenue=+4.7%
Additional Sources for FIGS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle